Your browser is no longer supported. Please, upgrade your browser.
ADAP [NASD]
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-0.93 Insider Own1.20% Shs Outstand155.18M Perf Week0.84%
Market Cap708.88M Forward P/E- EPS next Y-1.03 Insider Trans12.60% Shs Float126.69M Perf Month-4.37%
Income-139.70M PEG- EPS next Q-0.25 Inst Own79.20% Short Float3.18% Perf Quarter-26.07%
Sales3.60M P/S196.91 EPS this Y30.10% Inst Trans3.74% Short Ratio4.87 Perf Half Y-1.43%
Book/sh1.99 P/B2.42 EPS next Y-5.10% ROA-30.10% Target Price- Perf Year10.80%
Cash/sh2.16 P/C2.23 EPS next 5Y1.00% ROE-39.00% 52W Range3.79 - 13.40 Perf YTD-10.58%
Dividend- P/FCF- EPS past 5Y-24.90% ROI-39.10% 52W High-64.03% Beta2.21
Dividend %- Quick Ratio11.50 Sales past 5Y-15.10% Gross Margin- 52W Low27.18% ATR0.35
Employees462 Current Ratio11.50 Sales Q/Q-50.00% Oper. Margin- RSI (14)43.09 Volatility7.34% 7.23%
OptionableYes Debt/Eq0.00 EPS Q/Q-6.50% Profit Margin- Rel Volume0.51 Prev Close4.82
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume826.78K Price4.82
Recom2.40 SMA20-6.22% SMA50-7.08% SMA200-21.79% Volume0 Change0.00%
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
May-11-21 12:32PM  
08:00AM  
May-06-21 07:30AM  
Apr-27-21 04:30PM  
Apr-22-21 08:00AM  
Apr-07-21 01:09AM  
Feb-25-21 07:30AM  
06:15AM  
Feb-11-21 08:00AM  
Feb-06-21 01:03AM  
Dec-16-20 12:32PM  
Dec-07-20 11:32PM  
Nov-20-20 07:30AM  
Nov-19-20 09:00AM  
Nov-12-20 08:00AM  
Nov-09-20 03:18PM  
Nov-08-20 10:00AM  
Nov-06-20 11:01AM  
Nov-05-20 07:30AM  
06:15AM  
Oct-22-20 08:00AM  
Oct-16-20 12:41PM  
Oct-15-20 04:40PM  
Oct-13-20 12:04PM  
Oct-09-20 06:18AM  
Aug-28-20 10:30AM  
Aug-11-20 12:00PM  
Aug-10-20 07:40AM  
07:25AM  
Aug-06-20 07:30AM  
Jul-23-20 04:00PM  
Jul-22-20 08:00AM  
Jul-05-20 02:25PM  
Jun-23-20 11:26AM  
Jun-17-20 09:33AM  
08:52AM  
Jun-12-20 06:30AM  
Jun-08-20 10:30AM  
Jun-04-20 10:45AM  
Jun-02-20 04:37AM  
12:38AM  
Jun-01-20 09:39PM  
12:51PM  
11:01AM  
09:38AM  
06:09AM  
06:00AM  
04:15AM  
May-29-20 05:08PM  
02:20PM  
10:32AM  
10:24AM  
07:30AM  
May-19-20 07:02AM  
May-14-20 12:00PM  
08:55AM  
07:30AM  
May-12-20 08:00AM  
06:07AM  
Apr-29-20 08:00AM  
Apr-28-20 12:00PM  
08:00AM  
Mar-20-20 10:40PM  
Mar-11-20 11:35AM  
Feb-29-20 08:31AM  
Feb-27-20 07:30AM  
06:00AM  
Feb-24-20 03:15PM  
Feb-20-20 04:00PM  
Feb-18-20 08:00AM  
Feb-07-20 04:05PM  
Feb-05-20 11:30AM  
Feb-03-20 09:13AM  
Jan-24-20 04:30PM  
Jan-22-20 01:18PM  
08:48AM  
08:25AM  
06:48AM  
Jan-21-20 04:08PM  
Jan-17-20 12:00PM  
Jan-15-20 08:22AM  
Jan-14-20 12:29PM  
07:55AM  
02:08AM  
Jan-13-20 08:30AM  
02:00AM  
Dec-30-19 05:25AM  
Dec-16-19 05:45AM  
Dec-03-19 02:20PM  
08:30AM  
Nov-17-19 11:40AM  
Nov-16-19 02:00AM  
Nov-06-19 07:30AM  
Nov-01-19 08:00AM  
Oct-31-19 01:52PM  
06:09AM  
Oct-09-19 08:00AM  
Oct-01-19 08:00AM  
Sep-30-19 08:45AM  
Sep-16-19 06:41AM  
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TAYTON-MARTIN HELEN KATRINAChief Business OfficerMar 03Option Exercise0.161,785,000280,2451,800,000Mar 03 09:01 PM
Lunger JohnChief Patient Supply OfficerJan 19Sale5.674,35824,7087,346Jan 19 09:01 PM
Norry ElliotChief Medical OfficerJan 19Sale5.672,11111,9683,539Jan 19 09:01 PM
Rawcliffe AdrianChief Executive OfficerJan 19Sale5.679,87956,00913,529Jan 19 09:00 PM
Lunger JohnChief Patient Supply OfficerJan 12Sale6.151,0586,5091,767Jan 12 09:01 PM
Bertrand William C JRChief Operating OfficerJan 12Sale6.152,23413,7443,768Jan 12 09:01 PM
Rawcliffe AdrianChief Executive OfficerJan 12Sale6.152,70716,6543,695Jan 12 09:00 PM
Norry ElliotChief Medical OfficerJan 12Sale6.158415,1741,396Jan 12 09:00 PM
Bertrand William C JRChief Operating OfficerJan 04Sale5.333,49918,6425,864Jan 05 09:01 PM
Lunger JohnChief Patient Supply OfficerJan 04Sale5.331,0655,6741,760Jan 05 09:02 PM
Norry ElliotChief Medical OfficerJan 04Sale5.338454,5021,392Jan 05 09:00 PM
Rawcliffe AdrianChief Executive OfficerJan 04Sale5.334,96726,4646,737Jan 05 09:00 PM
Bertrand William C JRChief Operating OfficerDec 14Buy0.69207,000143,824284,808Dec 15 09:00 PM
Wood GavinChief Financial OfficerDec 14Buy0.6924,00016,55057,000Dec 16 09:00 PM
Rawcliffe AdrianChief Executive OfficerSep 01Sale8.512,77623,6373,076Sep 02 09:00 PM
TAYTON-MARTIN HELEN KATRINAChief Business OfficerAug 03Sale8.74200,0001,748,1800Aug 04 09:02 PM
Lunger JohnChief Patient Supply OfficerAug 03Sale9.254,82344,6138,066Aug 04 09:02 PM
Rawcliffe AdrianChief Executive OfficerAug 03Sale9.252,78825,7893,064Aug 04 09:01 PM
Wood GavinChief Financial OfficerJun 29Buy1.6233,00053,46033,000Jun 30 09:01 PM
Alleva Lawrence MDirectorJun 09Buy1.8912,90024,38112,900Jun 11 09:00 PM
Noble JamesDirectorMay 29Sale9.33500,0004,666,0000Jun 02 09:30 PM